Navigation Links
Marcadia and Lilly Sign Development, License Agreement for Novel Glucagon Program in Severe Hypoglycemia
Date:6/28/2010

INDIANAPOLIS, June 28 /PRNewswire-FirstCall/ -- Marcadia Biotech, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use than the current recombinant glucagon for the treatment of severe hypoglycemia. The program includes MAR531, a glucagon analog that is in preclinical development at Marcadia, as well as related backup compounds.

Under the terms of the agreement, Marcadia will continue to oversee development of the compound through regulatory approval in the U.S., while Lilly will be responsible for obtaining regulatory approval in countries outside the U.S. and for commercialization worldwide.  Financial terms of the collaboration were not disclosed.

"Glucagon is an important therapeutic for people with diabetes to treat an episode of severe hypoglycemia, but the currently marketed products require  reconstitution from a lyophilized (powder) form before administering an injection," said Enrique Conterno, president of Lilly Diabetes. "A new glucagon therapy that can be stored in solution form at room temperature and supplied in a convenient injection device could be an important advance for patients."

Fritz French, chief executive officer of Marcadia, added, "Lilly's long experience and expertise in diabetes, including its position as the market leader in the glucagon emergency kit space, was an important consideration for Marcadia. Their capabilities, combined with our unique peptide chemistry, which has been instrumental to all of our peptide discovery and development programs, should maximize the potential for this compound to benefit patients suffering from diabetes."

The companies plan to develop the short-acting glucagon analog to be supplied and stored in a single-use auto-injection "pen" device. MAR531 and related backup compounds were discovered through Marcadia's sponsored research agreement with Indiana University, Bloomington.

About Eli Lilly and Company

Eli Lilly and Company, a leading innovation-driven company, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Information about Lilly is available at www.lilly.com.    C-LLY

About Marcadia Biotech

Marcadia Biotech is a biopharmaceutical company focused on developing a broad portfolio of drug candidates for the treatment of diabetes and obesity. Using proprietary peptide chemistry, Marcadia seeks to develop candidates with unprecedented performance in key metabolic hormone pathways. Separately, the company is also developing a dual agonist of GIP and GLP-1 for the treatment of diabetes (MAR701) and a set of novel peptides that target GLP-1 biology. Founded in 2006, Marcadia is based in Carmel, Ind. For more information, visit http://www.marcadiabiotech.com.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company; Marcadia Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes
2. Lilly Declares Third-Quarter 2010 Dividend
3. Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths
4. Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations
5. Lilly to Acquire Global License to AXIRON Testosterone Solution From Acrux
6. Lillys Online, Interactive Health Education Program Receives Two Web Awards
7. Lilly Reports Fourth-Quarter and Full-Year 2009 Results
8. Lilly Confirms Date and Conference Call For Fourth-Quarter and Full-Year 2009 Financial Results Announcement
9. Lilly CEO Stresses Human Element in Driving Medical Innovation
10. Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
11. PDL BioPharma Announces New Licensing Agreement With Eli Lilly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2017)... LAWRENCE, Mass. , June 2, 2017  NxStage ... advancing renal care, today announced new findings demonstrating positive ... NxStage ® System One™. The data will be ... 2017, in Madrid, Spain . ... Knowledge to Improve Home Dialysis Network in ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, the ... announces the launch of a new website ... results of a clinical study that showed surprising ... with Gene-Eden-VIR/Novirin in individuals suffering from HPV warts, ... that there are no other treatments that clear ...
Breaking Medicine Technology:
(Date:6/20/2017)... ... June 20, 2017 , ... AMC Health , the leading provider of ... clinical trials market. Similar to its approach in demonstrating positive outcomes in the healthcare ... by proving the value of eVisits to support virtual studies. , In ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... With certifications ... Invisalign® in Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new ... complications that traditional orthodontics can cause for some patients, which is why they offer ...
(Date:6/20/2017)... , ... June 20, 2017 , ... Uniform Advantage ... collection featuring seven new products designed to create tailored looks and athleisure-inspired outfits. UA ... and cotton easy care stretch twill. , With trendy looks hitting the medical community, ...
(Date:6/20/2017)... Smithsburg, Maryland (PRWEB) , ... June 20, 2017 ... ... communication to the patient’s bedside, would like to officially welcome Anthony Stanowski, DHA, ... side-by-side with Dr. Stanowski whose insight and expertise in healthcare will provide invaluable ...
(Date:6/19/2017)... ... 2017 , ... The joyful summer wedding season is upon us, but it’s ... winter and wet spring have created ideal conditions for mosquitoes and ticks poised to ... pesky mosquitoes when a bride and groom are saying their "I do's,” observes Manuel ...
Breaking Medicine News(10 mins):